posam
 

As filed with the Securities and Exchange Commission on February 24, 2004

Registration No. 333-93853


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
———————
POST-EFFECTIVE AMENDMENT NO. 3 TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
———————
United Therapeutics Corporation
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware
(State or Other Jurisdiction of Incorporation or
Organization)
  52-1984749
(I.R.S. Employer
Identification Number)

1110 Spring Street
Silver Spring, MD 20910
(301) 608-9292

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
———————
Martine A. Rothblatt
Chairman and Chief Executive Officer
United Therapeutics Corporation
1110 Spring Street
Silver Spring, MD 20910
(301) 608-9292

(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
———————
Copies to:
Paul A. Mahon
Senior Vice President and General Counsel
United Therapeutics Corporation
1110 Spring Street
Silver Spring, MD 20910
(301) 608-9292

Approximate date of commencement of proposed sale of the securities to the public: Not applicable.

If any of the securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.      

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.      

 


 

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.      

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.      

If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box.      

 


 

EXPLANATORY STATEMENT

     Pursuant to this Post-Effective Amendment to its Registration Statement on Form S-3, as amended (Registration No. 333-93853), United Therapeutics Corporation deregisters all shares of its common stock, par value $0.01 per share, heretofore registered and not previously sold.

SIGNATURES

     Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Silver Spring, County of Montgomery, State of Maryland on the 23rd day of February, 2004.

             
    UNITED THERAPEUTICS CORPORATION    
    By:   /s/ Martine A. Rothblatt

Martine A. Rothblatt
Chairman and Chief Executive Officer
   

     Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates stated.

         
Signatures                  Title               Date
/s/ Martine A. Rothblatt

Martine A. Rothblatt
  Chairman and
Chief Executive Officer
  February 23, 2004
/s/ Fred T. Hadeed

Fred T. Hadeed
  Chief Financial Officer   February 19, 2004
/s/ Roger Jeffs

Roger Jeffs
  President, Chief Operating
Officer and Director
  February 23, 2004
/s/ Ricardo Balda

Ricardo Balda
  Director   February 23, 2004
/s/ Christopher Causey

Christopher Causey
  Director   February 20, 2004

 


 

         
/s/ Raymond A. Dwek

Raymond A. Dwek
  Director   February 19, 2004
/s/ R. Paul Gray

R. Paul Gray
  Director   February 23, 2004
/s/ H. Beecher Hicks, III

H. Beecher Hicks, III
  Director   February 20, 2004
/s/ Raymond Kurzweil

Raymond Kurzweil
  Director   February 19, 2004
/s/ Christopher Patusky

Christopher Patusky
  Director   February 23, 2004
 

Louis W. Sullivan
  Director